Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A

References

• Ortiz De Montellano PR. The Cytochrome P450 Oxidative System. In: Pearson PG, Wienkers LC, editors. Handbook of drug metabolism. Third Edition ed. Boca Raton, FL: CRC Press; 2019. p. 57–83.
   Google Scholar
• Coleman MD. Drug biotransformational systems – origins and aims. In: Human Drug Metabolism. Third Edition ed. Hoboken, NJ: Wiley-Blackwell; 2020. p. 17–97.
   Google Scholar
• Saiz-Rodríguez M, Almenara S, Navares-Gómez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 Polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020;8(4):94.
   PubMed Web of Science ®Google Scholar
• Wright WC, Chenge J, Chen T. Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. Liver Res. 2019;3(3–4):132–142.
   PubMedGoogle Scholar
• United States Food and Drug Administration, 2020, Drug development and drug interactions: Table of substrates, inhibitors and inducers, Available From 2021 Jan 26, https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
   Google Scholar
• Kawaguchi-Suzuki M, Stamper BD. Pharmacokinetic and pharmacogenomic considerations for the medicinal use of botanicals. In: Hume A, Orr KK, editors. Principles and Practice of Botanicals as an Integrative Therapy. Boca Raton, FL: CRC Press; 2019. p. 11–26.
   Google Scholar
• Yu J, Petrie ID, Levy RH, et al. Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration in 2017. Drug Metab Dispos. 2019;47(2):135–144.
   PubMed Web of Science ®Google Scholar
• Kato R, Nakamura Y, Chiesara E. Enhanced phenobarbital induction of liver microsomal drug-metabolizing enzymes in mice infected with murine hepatitus virus. Biochem Pharmacol. 1963;12:365–370.
   PubMed Web of Science ®Google Scholar
• Morgan ET. Regulation of Drug-metabolizing enzymes and drug metabolism by inflammatory responses. In: Xie W, editor. Drug metabolism in diseases. Cambridge, MA: Academic Press; 2017. p. 22–58.
   Google Scholar
• Mallick P, Taneja G, Moorthy B, et al. Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics–small molecule drug interactions. Expert Opin Drug Metab Toxicol. 2017;13(6):605–616.
   PubMed Web of Science ®Google Scholar
• Croyle MA. Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem. Expert Opin Drug Metab Toxicol. 2009;5(10):1189–1211.
   PubMed Web of Science ®Google Scholar
• Callahan SM, Ming X, Lu SK, et al. Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. J Pharmacol Exp Ther. 2005;312(2):492–501.
   PubMed Web of Science ®Google Scholar
• Callahan S, Boquet MP, Ming X, et al. Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. J Gene Med. 2006;8(5):566–576.
   PubMed Web of Science ®Google Scholar
• Callahan S, Wonganan P, Croyle MA. Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection. Virol J. 2008;5:111.
   PubMed Web of Science ®Google Scholar
• Wonganan P, Zamboni WC, Strychor S, et al. Croyle, MA drug-virus interaction: Effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model. Cancer Gene Ther. 2009;16(5):405–414.
   PubMed Web of Science ®Google Scholar
• Wonganan P, Clemens CC, Brasky K, et al. Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus. Mol Pharm. 2011;8(1):78–92.
   PubMed Web of Science ®Google Scholar
• Jonsson-Schmunk K, Wonganan P, Choi JH, et al. Integrin receptors play a key role in the regulation of hepatic CYP3A. Drug Metab Dispos. 2016;44(5):758–770.
   PubMed Web of Science ®Google Scholar
• Shah P, Guo T, Moore DD, et al. Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters. Drug Metab Dispos. 2014;42(1):172–181.
   PubMed Web of Science ®Google Scholar
• Becker DJ, Downs CJ, Martin LB. Multi-Scale Drivers of Immunological variation and consequences for infectious disease dynamics. Integr Comp Biol. 2019;59(5):1129–1137.
   PubMed Web of Science ®Google Scholar
• Bloom DE, Cadarette D. Infectious disease threats in the twenty-first century: Strengthening the global response. Front Immunol. 2019;28;10:549.
   Web of Science ®Google Scholar
• Roychoudhury S, Das A, Sengupta P, et al. Viral pandemics of the last four decades: Pathophysiology, health impacts and perspectives. Int J Environ Res Public Health. 2020 Dec;17(24):9411.
   PubMed Web of Science ®Google Scholar
• Xu X, Blanton L, Elal AIA, et al. Update: Influenza activity in the united states during the 2018-19 season and composition of the 2019-20 influenza vaccineMMWR Morb. Mortal. Wkly Rep. 2019;68(24):544–551.
   Google Scholar
• Ilunga Kalenga O, Moeti M, Sparrow A, et al. The ongoing ebola epidemic in the democratic republic of congo, 2018-2019. N Engl J Med. 2019;381(4):373–383.
   PubMed Web of Science ®Google Scholar
• Ollmann Saphire EA. Vaccine against Ebola Virus. Cell. 2020;181(1):6.
   PubMed Web of Science ®Google Scholar
• Frederiksen LSF, Zhang Y, Foged C, et al. The long road toward COVID-19 herd immunity: Vaccine platform technologies and mass immunization strategies. Front Immunol. 2020;11:1817.
   PubMed Web of Science ®Google Scholar
• Kleinrock M, Munoz E (2020) Global medicine spending and usage trends: Outlook to 2024. IQVIA Institute for Human Data Science. [cited 2021 Jan 26]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends
   Google Scholar
• World Health Organization. (2019) WHO Global Report on Traditional and Complementary Medicine 2019. Geneva: World Health Organization; License: CC BY-NC-SA 3.0 IGO
   Google Scholar
• Matz KM, Marzi A, Feldmann H. Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev Vaccines. 2019;18(12):1229–1242.
   PubMed Web of Science ®Google Scholar
• Huttner A, Combescure C, Grillet S, et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Sci Transl Med. 2017;9(385):eaaj1701.
   PubMed Web of Science ®Google Scholar
• Tapia MD, Sow SO, Ndiaye BP, et al. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2020;20(6):707–718.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• CDC COVID-19 Response Team. Food and drug administration. allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb. Mortal. Wkly Rep.. 2021;70(4):125–129.
   Google Scholar
• Trombetta CM, Gianchecchi E, Montomoli E. Influenza Vaccines: Evaluation of the safety profile. Hum. Vaccin. Immunother. 2018;14(3):657–670.
   Google Scholar
• National Center for Immunization and Respiratory Diseases (NCIRD) (2020) Weekly U.S. Influenza Surveillance Report: 2019-2020 Influenza Season Week 33 Ending 2020 Aug 15 Retrieved from https://www.cdc.gov/flu/weekly/index.htm (accessed 2020 Aug 25
   Google Scholar
• World Health Organization, (2019c, 28 February). Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season. Available From 2020 Aug 25 from https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/
   Google Scholar
• Sasso E, D’Alise AM, Zambrano N, et al., New viral vectors for infectious diseases and cancer. Semin Immunol. Aug 2020;50:101430.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses. 2020 Nov 18;12(11):1324.
   PubMed Web of Science ®Google Scholar
• Goldstein N, Bockstal V, Bart S, et al. Safety and immunogenicity of heterologous and homologous two dose regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. J Infect Dis. 2020 Sep 16;jiaa586. DOI:10.1093/infdis/jiaa586
   PubMedGoogle Scholar
• Li Y, Wang L, Zhu T, et al. Establishing China’s national standard for the recombinant adenovirus Type 5 Vector-Based ebola vaccine (Ad5-EBOV) Virus Titer. Hum Gene Ther Clin Dev. 2018 Dec;29(4):226–232.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021 Jan 13:NEJMoa2034201. Epub ahead of print. DOI:10.1056/NEJMoa2034201
   Web of Science ®Google Scholar
• Barrett JR, Belij-Rammerstorfer S, Dold C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2020 Dec 17. Epub ahead of print. DOI:10.1038/s41591-020-01179-4
   Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.
   PubMed Web of Science ®Google Scholar
• Croyle M, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008;3(10):e3548.
   PubMed Web of Science ®Google Scholar
• Richardson J, Yao MK, Tran KN, et al. Enhanced protection against ebola virus mediated by an improved adenovirus-based vaccine. PLoS One. 2009;4(4):e5208.
   PubMed Web of Science ®Google Scholar
• Choi J, Schafer SC, Zhang L, et al. A single sublingual dose of an adenovirus-based vaccine protects against lethal ebola challenge in mice and guinea pigs. Mol Pharm. 2012;9(1):156–167.
   PubMed Web of Science ®Google Scholar
• Choi J, Jonsson-Schmunk K, Qiu X, et al. A single dose respiratory recombinant adenovirus-based vaccine provides long-term protection for non-human primates from lethal ebola Infection. Mol Pharm. 2015;12(8):2712–2731.
   PubMed Web of Science ®Google Scholar
• Choi J, Schafer SC, Freiberg AN, et al. Bolstering Components of the immune response compromised by prior exposure to adenovirus: guided formulation development for a nasal ebola vaccine. Mol Pharm. 2015;12(8):2697–2711.
   PubMed Web of Science ®Google Scholar
• Francis T. Magill, TP cultivation of human influenza virus in an artificial medium. Science. 1935;82(2128):353–354.
   PubMedGoogle Scholar
• Daly K, Nguyen P, Woodland DL. Blackman, MA Immunodominance of major histocompatibility complex class I- restricted influenza virus epitopes can Be Influenced by the T-Cell Receptor Repertoire. J Virol. 1995;69(12):7416–7422.
   PubMed Web of Science ®Google Scholar
• Lee J, Fusco M, Saphire EO. An efficient platform for screening expression and crystallization of glycoproteins produced in human cells. Nat Protoc. 2009;4(4):592–604.
   PubMed Web of Science ®Google Scholar
• Schmittgen T. Livak, KJ Analyzing Real-Time PCR Data by the Comparative C(T) Method. Nat Protoc. 2008;3(6):1101–1108.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Aevermann BD, Anderson TK, et al. Influenza research database: an integrated bioinformatics resource for influenza virus research nucleic acids res. 2017;45(D1):D466–D474.
   Google Scholar
• Takagi S, Nakajima M, Mohri T. Post-transcriptional regulation of human pregnane x receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem. 2008;283(15):9674–9680.
   PubMed Web of Science ®Google Scholar
• Lim P, Tan W, Latchoumycandane C, et al. Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. Toxicol. In Vitro . 2007;21(8):1390–1401.
   PubMed Web of Science ®Google Scholar
• Tanii H, Shitara Y, Torii M, et al. Induction of Cytochrome P450 2A6 by Bilirubin in Human Hepatocytes. Pharmacol Pharm. 2013;4(2):182–190.
   Google Scholar
• Wonganan P, Jonsson-Schmunk K, Callahan SM, et al. Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome p450 3a during adenovirus infection. Drug Metab Dispos. 2014;42(7):1191–1201.
   PubMed Web of Science ®Google Scholar
• Yoshitsugu H, Nishimura M, Tateno C, et al. Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet. 2006;21(6):465–474.
   PubMed Web of Science ®Google Scholar
• Lv C, Huang L. Xenobiotic receptors in mediating the effect of sepsis on drug metabolism. Acta Pharm Sin B. 2020;10(1):33–41.
   PubMed Web of Science ®Google Scholar
• Hodges E, Connor J. Translational control by negative-strand RNA viruses: methods for the study of a crucial virus/host interaction. Methods. 2013;59(2):180–187.
   PubMed Web of Science ®Google Scholar
• Hayney M. Buck, JM effect of age and degree of immune activation on cytochrome p450 3a4 activity after influenza immunization. Pharmacotherapy. 2002;22(10):1235–1238.
   PubMed Web of Science ®Google Scholar
• Hayney M, Hammes RJ, Fine JP. Bianco, JA Effect of Influenza Immunization on CYP3A4 Activity. Vaccine. 2001;20:858–861.
   PubMed Web of Science ®Google Scholar
• Hayney MS, Muller D. Effect of Influenza Immunization on CYP3A4 Activity In Vivo. J Clin Pharmacol. 2003;3(12):1377–1381.
   Web of Science ®Google Scholar
• Radigan KA, Misharin AV, Chi M, et al. Modeling human influenza infection in the laboratory infect. Drug Resist. 2015;8:311–320.
   Google Scholar
• Koopman G, Mooij P, Dekking L, et al. Correlation between virus replication and antibody responses in macaques following infection with pandemic influenza A virus. J Virol. 2015;90(2):1023–1033.
   PubMed Web of Science ®Google Scholar
• Liebowitz D, Lindbloom JD, Brandl JR, et al. High titre neutralising antibodies to influenza after oral tablet immunisation: A Phase 1, randomised, placebo-controlled trial. Lancet Infect Dis. 2015;15(9):1041–1048.
   PubMed Web of Science ®Google Scholar
• Bajrovic I, Schafer SC, Romanovicz DK, et al. Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature. Sci Adv. 2020;6(10):eaau4819.
   PubMed Web of Science ®Google Scholar
• Jacob ST, Crozier I, Fischer WA, et al. Ebola virus disease. Nat Rev Dis Primers. 2020;6(1):13.
   PubMed Web of Science ®Google Scholar
• Siragam V, Wong G, Qiu XG. Animal models for filovirus infections. Zool Res. 2018 Jan 18;39(1):15–24.
   PubMed Web of Science ®Google Scholar
• Boyd DF, Wilson TL, Thomas PG. One hundred years of (influenza) immunopathology. Adv Virus Res. 2020;107:247–284.
   PubMed Web of Science ®Google Scholar
• Honce R, Wohlgemuth N, Meliopoulos VA, et al. Influenza in high-risk hosts-lessons learned from animal models. Cold Spring Harb Perspect Med. 2020 Dec 1;10(12):a038604.
   PubMed Web of Science ®Google Scholar
• Rudeck J, Bert B, Marx-Stoelting P, et al. Liver lobe and strain differences in the activity of murine cytochrome P450 enzymes. Toxicology. 2018 Jul;1:404–405:76-85.
   Google Scholar
• Hammer H, Schmidt F, Marx-Stoelting P, et al. Cross-species analysis of hepatic cytochrome P450 and transport protein expression. Arch Toxicol. 2021 Jan;95(1):117–133.
   PubMed Web of Science ®Google Scholar
• Lu C, Di L. In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development. Biopharm Drug Dispos. 2020 Feb;41(1–2):3–31.
   PubMed Web of Science ®Google Scholar
• Fislová T, Gocník M, Sládková T, et al. Multiorgan distribution of human influenza a virus strains observed in a mouse model. Arch Virol. 2009;154(3):409–419.
   PubMed Web of Science ®Google Scholar
• Jan E, Mohr I, Walsh D, et al. Guide to mRNA translation strategies in virus-infected cells. Ann Rev Virol. 2016;3(1):283–307.
   PubMed Web of Science ®Google Scholar
• Yanagiya A, Svitkin Y, Shibata S, et al. H. Mol Cell Biol. 2009;29(6):1661–1669.
   PubMed Web of Science ®Google Scholar
• Scheper G, Proud C. Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem. 2002;269(11):5359.
   Google Scholar
• Burgui I, Yángüez E, Sonenberg N, et al. Influenza virus mRNA translation revisited: Is the eIF4E cap-binding factor required for viral mRNA translation? J Virol. 2007;81(22):12427–12438.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Moriyama Y, Ikari A, et al. Surface Localization of the nuclear receptor CAR in Influenza a Virus-Infected Cells Biochem. Biophys Res Commun. 2008;368(3):550–555.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ong SS, Chai SC, et al. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol. 2012;8(7):803–817.
   PubMed Web of Science ®Google Scholar
• Cantoni D, Rossman JS. Ebolaviruses: New roles for old proteins. PLoS Negl Trop Dis. 2018;12(5):e0006349.
   PubMed Web of Science ®Google Scholar
• Wang X. Evaluation of cytochrome p450 enzymes in drug interactions. In: Wu J, editor. cytochrome P450 Enzymes: Biochemistry, pharmacology and health implications. New York: Nova Science Publishers; 2014. p. 51–87.
   Google Scholar
• Ye F, Snider AK, Ginsberg MH. Talin and kindlin: the one-two punch in integrin activation. Front Med. 2014;8(1):6–16.
   PubMed Web of Science ®Google Scholar
• Schornberg KL, Shoemaker CJ, Dube D, et al. White, JM Alpha5Beta1-Integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A. 2009;106(19):8003–8008.
   PubMed Web of Science ®Google Scholar
• Takada A, Watanabe S, Ito H, et al. Kawaoka downregulation of beta1 integrins by ebola virus glycoprotein. Implication for Virus Entry. Virology. 2000;278(1):20–26.
   PubMed Web of Science ®Google Scholar
• Sigrist CJA, Bridge A, Le Mercier P, et al. Role for Integrins in Host Cell Entry by SARS-CoV-2. Antiviral Res. 2020;177:104759.
   PubMed Web of Science ®Google Scholar
• Davis PJ, Lin H-Y, Hercbergs A, et al. Coronaviruses and Integrin ∝vβ3: Does thyroid hormone modify the relationship? Endocr Res. 2020;45(3):210–215.
   PubMed Web of Science ®Google Scholar
• Amacher DE. The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors. Expert Opin Drug Metab Toxicol. 2016;12(12):1463–1477.
   PubMed Web of Science ®Google Scholar
• Barberis I, Myles P, Ault SK, et al. Evolution of influenza control through vaccination: From the first monovalent vaccine to universal vaccines. J Prev Med Hyg. 2016;57(3):E115–E120.
   PubMedGoogle Scholar
• Streetman D, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: A Review of In-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187–216.
   Google Scholar
• Chiou W, Jeong HY, Wu TC. Ma, C use of the erythromycin breath test for in vivo assessment of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther. 2001;70:305–310.
   PubMed Web of Science ®Google Scholar
• Hohmann N, Haefeli WE, Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol. 2016;12(5):479–497.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Gupta S, Ramanathan R, et al. Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009;3(3):162–170.
   PubMedGoogle Scholar
• Mandrioli R, Mercolini L. Metabolism of drugs used in the therapy of seizures: An analytical point of view. part 1. Curr Drug Metab. 2017;18(8):735–756.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JL, Howes LG. Drug interactions of direct-acting oral anticoagulants. Drug Saf. 2016;39(9):841–845.
   PubMed Web of Science ®Google Scholar
• Ma YJ, Jiang DQ, Meng JX, et al. Theophylline: a review of population pharmacokinetic analyses. J Clin Pharm Ther. 2016;41(6):594–601.
   PubMed Web of Science ®Google Scholar
• Sadler NC, Nandhikonda P, Webb-Robertson BJ, et al. Hepatic Cytochrome p450 activity, abundance, and expression throughout human development. Drug Metab Dispos. 2016;44(7):984–991.
   PubMed Web of Science ®Google Scholar
• Krekels EHJ, Rower JE, Constance JE, et al. Hepatic drug metabolism in pediatric patients. In: Wen X, editor. Drug Metabolism and Diseases. Cambridge, MA: Academic Press; 2017. p. 181–206.
   Google Scholar
• Gallo P, De Vincentis A, Pedone C, et al. Drug-drug interactions involving CYP3A4 and P-glycoprotein in hospitalized elderly patients. Eur J Intern Med. 2019;65:51–57.
   PubMed Web of Science ®Google Scholar
• Gallo Marin B, Aghagoli G, Lavine K, et al. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2020;31(1):e2146.
   Web of Science ®Google Scholar
• May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69–83.
   PubMed Web of Science ®Google Scholar
• Berinstein E, Levy A. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. Expert Opin Drug Metab Toxicol. 2017;13(9):973–983.
   PubMed Web of Science ®Google Scholar
• Waheed Y, Malik S, Khan M, et al. The world after ebola: An overview of ebola complications, vaccine development, lessons learned, financial losses, and disease preparedness. Crit Rev Eukaryot Gene Expr. 2019;29(1):77–84.
   Google Scholar